Related Experiment Videos
Use of ciprofloxacin in an infant with ventriculitis
J G Goepp1, C K Lee, T Anderson
1Department of Pediatrics, Johns Hopkins Hospital, Baltimore, Maryland 21205.
The Journal of Pediatrics
|August 1, 1992
Insights
Ciprofloxacin effectively treated ventriculitis in a neonate caused by a resistant Enterobacter cloacae strain. Pharmacokinetic data suggest sufficient cerebrospinal fluid drug concentrations were achieved.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Pharmacology
Background:
- Neonatal ventriculitis poses significant treatment challenges, especially with multidrug-resistant pathogens.
- Enterobacter cloacae is an opportunistic pathogen that can cause severe infections in neonates.
Observation:
- A neonate presented with ventriculitis attributed to a multiply resistant strain of Enterobacter cloacae.
- Treatment with ciprofloxacin was initiated to address the infection.
Findings:
- Successful clinical outcome was achieved with ciprofloxacin therapy.
- Limited pharmacokinetic studies demonstrated adequate ciprofloxacin penetration into the cerebrospinal fluid.
Implications:
- Ciprofloxacin represents a potential therapeutic option for neonatal ventriculitis caused by resistant Enterobacter cloacae.
- Further pharmacokinetic and clinical studies are warranted to confirm efficacy and safety in this population.
Abstract:
Ciprofloxacin was used successfully in a neonate with ventriculitis caused by a multiply resistant strain of Enterobacter cloacae. Limited pharmacokinetic data indicated that adequate concentrations of drug could be attained in cerebrospinal fluid.